[Organ preservation for rectal cancer: What are the arguments in favor of radiotherapy?]

Cancer Radiother. 2022 Oct;26(6-7):766-770. doi: 10.1016/j.canrad.2022.06.013. Epub 2022 Aug 19.
[Article in French]

Abstract

Standard care for rectal cancers relies on both tumor (location relative to the sphincter, T and N stage, sphincter involvement) and patients characteristics. Radical surgery (total mesorectal excision) following short-course radiotherapy (RT) or standard chemo-radiotherapy, associated with induction or consolidation chemotherapy (total neoadjuvant treatment), remains the cornerstone of locally advanced rectal cancer (T3cd, T4 and/or N+) treatment. Nevertheless, for early stages, this radical resection could be avoided in favor of conservative approaches combining RT (external, contact, brachytherapy) with or without chemotherapy (concurrent, induction or consolidative), or even be limited, for good responders, to a local excision with view of organ-preservation strategies. This conservative approach could also be offered selectively to patients with complete clinical response after the induction sequence, irrespective of initial tumor characteristics. The Watch and Wait strategy relies on clinical, endoscopic and radiological evaluations, as well as sustained surveillance. Ongoing studies aim to improve response rates, either with chemotherapy intensification, or RT boost dose escalation with brachytherapy or contact-therapy.

Keywords: Cancer du rectum; Clinical complete response; Neoadjuvant therapy; Organ preservation; Préservation d’organe; Rectal cancer; Réponse clinique complète; Traitement néoadjuvant; Watch and Wait.

Publication types

  • Review

MeSH terms

  • Chemoradiotherapy*
  • Humans
  • Neoadjuvant Therapy
  • Neoplasm Recurrence, Local
  • Organ Preservation
  • Rectal Neoplasms* / pathology
  • Rectal Neoplasms* / radiotherapy
  • Treatment Outcome
  • Watchful Waiting